Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Inflammation
Erschienen in: Inflammation 2/2012

01.04.2012

Parthenolide, a Sesquiterpene Lactone, Expresses Multiple Anti-cancer and Anti-inflammatory Activities

verfasst von: Vivek Bhakta Mathema, Young-Sang Koh, Balkrishna Chand Thakuri, Mika Sillanpää

Erschienen in: Inflammation | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Parthenolide, a naturally occurring sesquiterpene lactone derived from feverfew (Tanacetum parthenium), exhibits exceptional anti-cancer and anti-inflammatory properties, making it a prominent candidate for further studies and drug development. In this review, we briefly investigate molecular events and cell-specific activities of this chemical in relation to cytochrome c, nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB), signal transduction and activation of transcription (STAT), reactive oxygen species (ROS), TCP, HDACs, microtubules, and inflammasomes. This paper reports that parthenolide shows strong NF-κB- and STAT-inhibition-mediated transcriptional suppression of pro-apoptotic genes. This compound acts both at the transcriptional level and by direct inhibition of associated kinases (IKK-β). Similarly, this review discusses parthenolide-induced ROS-mediated apoptosis of tumor cells via the intrinsic apoptotic signaling pathway. The unique ability of this compound to not harm normal cells but at the same time induce sensitization to extrinsic as well as intrinsic apoptosis signaling in cancer cells provides an important, novel therapeutic strategy for treatment of cancer and inflammation-related disorders.
Literatur
1.
Marles, R.J., L. Pazos-Sanou, C.M. Compadre, J.M. Pezzuto, E. Bloszyk, and J. Arnason. 1995. Sesquiterpene lactones revisited: recent developments in the assessment of biological activities and structure relationships. Recent Advances in Phytochemistry 29: 333–356.
2.
Smolinski, A.T., and J.J. Pestka. 2005. Comparative effects of the herbal constituent parthenolide (Feverfew) on lipopolysaccharide-induced inflammatory gene expression in murine spleen and liver. Journal of Inflammation 2: 1–6.CrossRef
3.
Baud, V., and M. Karin. 2009. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nature Reviews Drug Discovery 8: 33–40.PubMedCrossRef
4.
Karin, M., and Y.B. Beriah. 2000. Phosphorylation meets ubiquitination: the control of NF-[kappa] B activity. Annual Review Immunology 18: 621–663.CrossRef
5.
Bernhard, S., N. Matthes, N.H. El Armouche, K. Neubauer, and G. Ramadori. 2001. The bcl, NFκB and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-β or TNF-α on activated hepatic stellate cells. European Journal of Cell Biology 80: 554–561.CrossRef
6.
Tapia, P.C. 2006. Sublethal mitochondrial stress with an attendant stoichiometric augmentation of reactive oxygen species may precipitate many of the beneficial alterations in cellular physiology produced by caloric restriction, intermittent fasting, exercise and dietary phytonutrients: "Mitohormesis" for health and vitality. Meidical Hypotheses 66: 832–843.CrossRef
7.
Payne, C.M., C. Weber, C.C. Skillicorn, K. Dovrak, H. Bernstein, H. Holubec, et al. 2007. Deoxycholate induces mitochondrial oxidative stress and activates NF-kB through multiple mechanisms in HCT-116 colon epithelial cells. Carcinogenesis 28: 215–222.PubMedCrossRef
8.
Li, N., and M. Karin. 1998. Ionizing radiation and short wavelength UV activate NF-κB through two distinct mechanisms. Proceedings of the National Academy of Sciences 95: 13012–13017.CrossRef
9.
Zhang, S., C.N. Ong, and H.M. Shen. 2004. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Letters 208: 143–153.PubMedCrossRef
10.
Tacchini, L., C. DePonti, E. Matteucci, R. Follis, and M.A. Desiderio. 2004. Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis 25: 2089–2100.PubMedCrossRef
11.
Zhao, L.J., Y.H. Xu, and Y. Li. 2009. Effect of parthenolide on proliferation and apoptosis in gastric cancer cell line SGC7901. Journal of Digestive Disorder 10: 172–180.CrossRef
12.
Benjamin, H.B., B.K. Kwoka, M.K. Ndubuisia, M. Elofssona, and C.M. Crews. 2001. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IκB kinase. Chemical Biology 8: 759–766.CrossRef
13.
Dai, Y., M.L. Guzman, S. Chen, L. Wang, S.K. Yeung, X.Y. Pei, et al. 2010. The NF (nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. British Journal of Haematology 151: 70–83.PubMedCrossRef
14.
Jenkins, C., S. Hewamana, A. Gilkes, S. Neelakantan, P. Crooks, K. Mills, et al. 2008. Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia. British Journal of Hematology 143: 661–671.CrossRef
15.
Hewamana, S., T.T. Lin, C. Jenkins, A.K. Burnett, C.T. Jordan, C. Fegan, et al. 2008. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clinical Cancer Research 14: 8102–8111.PubMedCrossRef
16.
Marfurt, J., F. Chalfein, P. Prayoga, F. Wabiser, E. Kenangalem, and K.A. Piera. 2011. Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax. Antimicrobial Agents and Chemotherapy 55: 96–66.
17.
Lamkanfi, M., and V.M. Dixit. 2009. The inflammasomes. PLoS Pathogen 5: e1000510.CrossRef
18.
Rajan, J.V., D. Rodriguez, E.A. Miao, and A. Aderem. 2011. The NLRP3 inflammasome detects encephalomyocarditis virus and vesicular stomatitis virus infection. The Journal of Virology 85: 4167–4172.CrossRef
19.
Pelegrin, P., and A. Surprenant. 2009. The P2X7 receptor–pannexin connection to dye uptake and IL-1β release. Purinergic Signal 5: 129–137.PubMedCrossRef
20.
Martinon, F., A. Mayor, and J. Tschopp. 2009. The inflammasomes: guardians of the body. Annual Review of Immunology 27: 229–265.PubMedCrossRef
21.
Hornung, V., F. Bauernfeind, A. Halle, E.O. Samstad, H. Kono, K.L. Rock, et al. 2008. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Natural Immunology 9: 847–856.CrossRef
22.
Cassel, S.L., S.C. Eisenbarth, S.S. Iyer, J.J. Sadler, O.R. Colegio, L.A. Tephly, et al. 2008. The Nalp3 inflammasome is essential for the development of silicosis. Proceedings of the National Academy of Sciences 105: 9035–9040.CrossRef
23.
Martinon, F., V. Petrilli, A. Mayor, A. Tardivel, and J. Tschopp. 2006. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237–241.PubMedCrossRef
24.
Juliana, C., T. Fernandes-Alnemri, J. Wu, P. Datta, L. Solorzano, J.W. Yu, et al. 2010. Anti-inflammatory compounds parthenolide and bay 11-7082 are direct inhibitors of the inflammasome. The Journal of Biological Chemistry 285: 9792–9802.PubMedCrossRef
25.
Dinarello, C.A. 1998. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. International Reviews of Immunolology 16: 457–499.CrossRef
26.
Steele, A.J., D.T. Jones, K. Ganeshaguru, V.M. Duke, B.C. Yogashangary, J.M. North, et al. 2006. The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro. Leukemia 20: 1073–1079.PubMedCrossRef
27.
Herrera, F., V. Martin, J. Rodriguez-Blanco, G. García-Santos, I. Antolín, and C. Rodriguez. 2005. Intracellular redox state regulation by parthenolide. Biochemical and Biophysical Research Communications 332: 321–325.PubMedCrossRef
28.
Hampton, M.B., and S. Orrenius. 1998. Redox regulation of apoptotic cell death. Biofactors 8: 1–5.PubMedCrossRef
29.
Nakshatri, H., S.E. Rice, and P.B. Nakshatri. 2004. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23: 7330–7344.PubMedCrossRef
30.
Winterbourn, C.C., and M.B. Hampton. 2008. Thiol chemistry and specificity in redox signaling. Free Radical Biology and Medicine 45: 549–561.PubMedCrossRef
31.
Lee, H., M.K. Cha, and I.H. Kim. 2000. Activation of thiol-dependent antioxidant activity of human serum albumin by alkaline pH is due to the B-like conformational change. Archives of Biochemistry and Biophysics 380: 309–318.PubMedCrossRef
32.
Pajak, B., B. Gajkowska, and A. Orzechowski. 2008. Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells. Folia Histochemica et Cytobiologica 46: 129–135.PubMedCrossRef
33.
Sun, Y., D.K. St Clair, Y. Xu, P.A. Crooks, and W.H. StClair. 2010. A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Cancer Research 70: 2880–2890.PubMedCrossRef
34.
Zunino, S.J., J.M. Ducore, and D.H. Storms. 2007. Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells. Cancer Letters 254: 119–127.PubMedCrossRef
35.
Zhang, S., C.N. Ong, and H.M. Shen. 2004. Involvement of proapoptotic bcl-2 family members in parthenolide-induced mitochondrial dysfunction and apoptosis. Cancer Letters 211: 175–188.PubMedCrossRef
36.
Li, H., H. Zhu, C.J. Xu, and J. Yuan. 1998. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491–501.PubMedCrossRef
37.
Sahler, J., J.J. Bernard, S.L. Spinelli, N. Blumberg, and R.P. Phipps. 2011. The Feverfew plant-derived compound, parthenolide enhances platelet production and attenuates platelet activation through NF-κB inhibition. Thrombosis Research 27: 426–434.CrossRef
38.
O’Brien, J.J., C.J. Baglole, T.M. Bates, N. Blumberg, C.W. Francis, and R.P. Phipps. 2009. 15-Deoxy-delta12, 14 prostaglandin J2-induced heme oxygenase-1 in megakaryocytes regulates thrombopoiesis. Journal of Thrombosis and Haemostasis 7: 182–189.PubMedCrossRef
39.
Weng, S.X., M.H. Sui, S.C. Wang, G. Xu, J. Ma, J. Shan, et al. 2009. Parthenolide inhibits proliferation of vascular smooth muscle cells through induction of G0/G1 phase cell cycle arrest. Journal of Zhejiang University 10: 528–535.PubMedCrossRef
40.
Meyer, T., and U. Vinkemeier. 2007. STAT nuclear translocation: potential for pharmacological intervention. Expert Opinion on Therapeutic Targets 11: 1355–1365.PubMedCrossRef
41.
Carlisi, D., A. D’Anneo, L. Angileri, M. Lauricella, S. Emanuele, A. Santulli, et al. 2011. Parthenolide sensitizes hepatocellular carcinoma cells to trail by inducing the expression of death receptors through inhibition of STAT3 activation. Journal of Cellular Physiololgy 226: 1632–1641.CrossRef
42.
Guzman, M.L., R.M. Rossi, L. Karnischky, X. Li, D.R. Peterson, D.S. Howard, et al. 2005. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105: 4163–4169.PubMedCrossRef
43.
Ganten, T.M., T.L. Haas, J. Sykora, H. Stahl, M.R. Sprick, S.C. Fas, et al. 2004. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death and Differenciation 11: S86–S96.CrossRef
44.
Chen, K.F., W.T. Tai, T.H. Liu, H.P. Huang, Y.C. Lin, C.W. Shiau, et al. 2010. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clinical Cancer Research 16: 5189–5199.PubMedCrossRef
45.
Sobota, R., M. Szwed, A. Kasza, M. Bugno, and T. Kordula. 2002. Parthenolide Inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family. Biochemical and Biophysical Research Communications 267: 329–333.CrossRef
46.
Burton, P.R. 1966. A Comparative electron microscopic study of cytoplasmic microtubules and axial unit tubules in a spermatozoon and a protozoan. Journal of Morphology 120: 397–423.CrossRef
47.
Fonrose, X., A. Frédéric, E. Soleilhac, B. David, I. Pouny, J.C. Cintrat, et al. 2007. Parthenolide inhibits tubulin carboxypeptidase activity. Cancer Research 67: 3371–3378.PubMedCrossRef
48.
Zhou, J., and P. Giannakakou. 2005. Targeting microtubules for cancer chemotherapy. Current Medicinal Chemistry-Anti-Cancer Agents 5: 65–71.PubMedCrossRef
49.
Mialhe, A., L. Lafanechere, and I. Treilleux. 2001. Tubulin detyrosination is a frequent occurrence in breast cancers of poor prognosis. Cancer Research 61: 5024–5027.PubMed
50.
Kato, C., K. Miyazaki, and A. Nakagawa. 2004. Low expression of human tubulin tyrosine ligase and suppressed tubulin tyrosination/detyrosination cycle are associated with impaired neuronal differentiation in neuroblastomas with poor prognosis. International Journal of Cancer 112: 365–375.CrossRef
51.
Soucek, K., A. Kamaid, A.D. Phung, L. Kubala, J.C. Bulinski, R.W. Harper, et al. 2006. Normal and prostate cancer cells display distinct molecular profiles of α-tubulin posttranslational modifications. Prostate 66: 954–965.PubMedCrossRef
52.
Lafanechere, L., and D. Job. 2000. The third tubulin pool. Neurochem Research 25: 11–18.CrossRef
53.
Akan, I., S. Akan, H. Akca, B. Savas, and T. Ozben. 2005. Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and Buthionine sulfoximine. Cancer Cell International 5: 22.PubMedCrossRef
54.
Heng, H.H., J.B. Stevens, G. Liu, S.W. Bremer, and C.J. Ye. 2004. Imaging genome abnormalities in cancer research. Cell and Chromosomes 5: 22.
55.
Kanda, N., H. Seno, Y. Konda, H. Marusawa, M. Kanai, and T. Nakajima. 2004. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 23: 4921–4929.PubMedCrossRef
56.
Wu, C., F. Chen, J.W. Rushing, X. Wang, H.J. Kim, G. Huang, et al. 2006. Antiproliferative activities of parthenolide and golden feverfew extract against three human cancer cell lines. Journal of Medicinal Food 9: 55–61.PubMedCrossRef
57.
Wang, W., M. Adachi, R. Kawamura, H. Sakamoto, T. Hayashi, T. Ishida, et al. 2006. Parthenolide-induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity. Apoptosis 11: 2225–2235.PubMedCrossRef
58.
Gopal, Y.N., T.S. Arora, and M.W. Dyke. 2007. Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated. Chemical Biology 14: 813–823.CrossRef
59.
Minucci, S., and P.G. Pelicci. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews Cancer 6: 38–51.PubMedCrossRef
Metadaten
Titel
Parthenolide, a Sesquiterpene Lactone, Expresses Multiple Anti-cancer and Anti-inflammatory Activities
verfasst von
Vivek Bhakta Mathema
Young-Sang Koh
Balkrishna Chand Thakuri
Mika Sillanpää
Publikationsdatum
01.04.2012
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 2/2012
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-011-9346-0

Weitere Artikel der Ausgabe 2/2012

Inflammation 2/2012 Zur Ausgabe

OriginalPaper

The New Vitamin E Derivative, ETS-GS, Protects Against Cecal Ligation and Puncture-Induced Systemic Inflammation in Rats

OriginalPaper

Lung Immunoreactivity and Airway Inflammation: Their Assessment After Scorpion Envenomation

OriginalPaper

Inflammatory Markers: Exhaled Nitric Oxide and Carbon Monoxide During the Ovarian Cycle

OriginalPaper

Changes in Peripheral CD4+CD25high Regulatory T Cells in the Acute-on-Chronic Liver Failure Patients with Plasma Exchange Treatment

OriginalPaper

The Role of Inflammation and COX-Derived Prostanoids in the Effects of Bradykinin on Isolated Rat Aorta and Urinary Bladder

OriginalPaper

Elevated Expression of β1,4-Galactosyltransferase-I in Cartilage and Synovial Tissue of Patients with Osteoarthritis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

17.04.2024 | DGIM 2024 | Nachrichten

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise